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Background. Manganese-enhanced MRI (MEMRI) has the potential to identify viable myocardium and quantify
calcium inux and handling. Two distinct manganese contrast media have been developed for clinical application, man-
gafodipir and EVP1001-1, employing dierent strategies to mitigate against adverse eects resulting from calcium-channel
agonism. Mangafodipir delivers manganese ions as a chelate, and EVP1001-1 coadministers calcium gluconate. Using
myocardial T1 mapping, we aimed to explore chelated and nonchelated manganese contrast agents, their mechanism of
myocardial uptake, and their application to infarcted hearts. Methods. T1 mapping was performed in healthy adult male
Sprague-Dawley rats using a 7T MRI scanner before and after nonchelated (EVP1001-1 or MnCl2 (22 μmol/kg)) or chelated
(mangafodipir (22–44 μmol/kg)) manganese-based contrast media in the presence of calcium channel blockade (diltiazem
(100–200 μmol/kg/min)) or sodium chloride (0.9%). A second cohort of rats underwent surgery to induce anterior myocardial
infarction by permanent coronary artery ligation or sham surgery. Infarcted rats were imaged with standard gadolinium
delayed enhancement MRI (DEMRI) with inversion recovery techniques (DEMRI inversion recovery) as well as DEMRI T1
mapping. A subsequent MEMRI scan was performed 48 h later using either nonchelated or chelated manganese and T1
mapping. Finally, animals were culled at 12 weeks, and infarct size was quantied histologically with Masson’s trichrome
(MTC). Results. Both manganese agents induced concentration-dependent shortening of myocardial T1 values. is was
greatest with nonchelated manganese, and could be inhibited by 30–43% with calcium-channel blockade. Manganese imaging
successfully delineated the area of myocardial infarction. Indeed, irrespective of the manganese agent, there was good
agreement between infarct size on MEMRI T1 mapping and histology (bias 1.4%, 95% CI −14.8 to 17.1 P> 0.05). In contrast,
DEMRI inversion recovery overestimated infarct size (bias 11.4%, 95% CI −9.1 to 31.8 P  0.002), as did DEMRI T1 mapping
(bias 8.2%, 95% CI −10.7 to 27.2 P  0.008). Increased manganese uptake was also observed in the remote myocardium, with
remote myocardial ∆T1 inversely correlating with left ventricular ejection fraction after myocardial infarction (r  0.61,
P  0.022). Conclusions. MEMRI causes concentration and calcium channel-dependent myocardial T1 shortening. MEMRI
with T1 mapping provides an accurate assessment of infarct size and can also identify changes in calcium handling in the
remote myocardium. is technique has potential applications for the assessment of myocardial viability, remodelling,
and regeneration.
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1. Introduction
With major and sustained advances in imaging techniques
over the past 3 decades, magnetic resonance imaging (MRI),
along with other advanced modalities such as positron
emission tomography (PET), has become an essential ele-
ment to noninvasive structural and functional cardiac im-
aging [1–3]. Current standard clinical methods use inversion
recovery-delayed enhancement sequences after gadolinium-
based contrast administration to imagemyocardial scar.)is
allows assessment of viability by assessing the transmural
extent of myocardial scar and is used to predict prognosis,
guiding the appropriateness of coronary revascularization
[4], with excellent reproducibility [5]. Although an invalu-
able tool in viability assessment, the nonselective passive
extracellular redistribution of gadolinium is unable to
characterise and deﬁne viable myocardium directly [6].
Indeed, quantiﬁcation by gadolinium delayed enhancement
MRI (DEMRI) is subject to overestimation of acute infarct
size due to tissue oedema [7]. It is also associated with
imaging artefact and interpretation bias in challenging pa-
tient populations. Furthermore, whilst signiﬁcant advances
have enabled multiparametric MRI assessment of gadoli-
nium distribution and dynamics to help determine aetiology
[8], in practice the diﬀerent patterns of late enhancement are
neither completely speciﬁc nor sensitive for diﬀerent forms
of cardiac pathology where signiﬁcant overlap is seen, as
with aortic stenosis and cardiac sarcoidosis [9–11].
)ere has been increasing interest in a range of alternative
contrast media [12] to broaden the capabilities and functional
assessments of MRI. Manganese, a paramagnetic calcium
analogue, enters active cardiomyocytes via voltage-gated
calcium channels, increasing MRI-detectable T1 relaxivity
[13]. As such, manganese-enhanced MRI (MEMRI) has the
potential to quantify calcium inﬂux and handling directly and
to identify functional cardiomyocytes actively cycling cal-
cium. Manganese-based contrast media can exist in either
chelated (e.g. mangafodipir, manganese dipyridoxyl di-
phosphate, MnDPDP) or nonchelated forms (e.g. EVP1001-1,
manganese gluconate with calcium gluconate [14]), and their
uptake appears predominantly dependent on the activity of
voltage-gated calcium channels during excitation-contraction
coupling [15–17]. )e diﬀerent formulations of these man-
ganese contrast media reﬂect diﬀerent strategies to address
adverse eﬀects of manganese resulting from calcium-channel
agonism which would otherwise be prohibitive to clinical use.
Mangafodipir delivers manganese ions in the form of a che-
lated agent, similar to conventional MRI contrast agents,
resulting in a lower eﬀective circulating dose of manganese
ions. Conversely, EVP1001-1 utilises coadministration of
calcium, in the form of calcium gluconate, to negate toxicity.
Both techniques have established safety and tolerability in
clinical studies as well as eﬃcacy in MRI contrast imaging.
Whilst short-term cardiac safety of intravenous MnCl2
has been suggested in a pilot study of 15 healthy volunteers
at an equivalent molar dose [18], due to the risk of acute
toxicity in cardiac patients, there is no expectation that
MnCl2 be developed further for clinical utility. However,
given that established clinical safety has been demonstrated
for both EVP1001-1 and mangafodipir at doses required for
cardiac MRI, there is widespread application for both
mangafodipir and EVP1001-1, notably for cardiac imaging.
Preclinical studies with mangafodipir and MnCl2 in healthy
myocardium and EVP1001-1 in myocardial infarction
models have described myocardial T1 shortening properties
[19] and demonstrated favourable agreement with histo-
logical infarct assessment [20]. Moreover, recent preclinical
studies have suggested that MEMRI can lead to better infarct
discrimination and the identiﬁcation of viable myocardium
[21] as well as the ability to assess engraftment of myocardial
stem cells [22].
Despite longstanding knowledge of the paramagnetic
properties of manganese, the development and clinical
translation of manganese contrast agents have been limited
by early issues with toxicity and the subsequent widespread
utility of gadolinium agents which have since dominated
clinical use in the ﬁeld. More recently, with concerns about
neurological accumulation of some gadolinium agents
[23–25], and as problems with acute manganese toxicity
have been overcome, there is scope to revisit this agent with
high potential in cardiac imaging.
Given the potential beneﬁts of MEMRI, we aimed to
compare myocardial enhancement using chelated and
nonchelated manganese-based contrast media and to de-
termine the contribution of calcium channels to their up-
take.)is study represents a novel head-to-head comparison
of three manganese contrast agents, using T1 mapping to
assess and compare their respective T1 shortening proper-
ties, utility and accuracy in quantifying myocardial in-
farction as compared with DEMRI (inversion recovery and
T1 mapping) and histological analysis, and explore altered
calcium handling in remodelling myocardium. )is pre-
clinical work is crucial to inform clinical translation and
further development of the potential of MEMRI in myo-
cardial viability assessment.
2. Methods
All studies were approved by the University of Edinburgh
Animal Welfare and Ethical Review Body and were carried
out in accordance with the UK Home Oﬃce Animals
(Scientiﬁc Procedures) Act 1986. Male Sprague-Dawley rats
(250–400 g, n � 55) were purchased from Charles River Ltd
(Haddington, UK) and housed, with free access to food and
water, in the Central Bioresearch Services, University of
Edinburgh for 7 days prior to use in the study.
2.1.MagneticResonance Imaging. All MRI experiments were
performed using a 7T horizontal bore NMR spectrometer
(Agilent Technologies, Yarnton, UK), equipped with a high-
performance gradient insert (120mm inner diameter),
maximum gradient strength 400mT/m. Rats were anaes-
thetised with 1.5–2% isoﬂurane (Zoetis Ltd., London UK) in
oxygen/air (50/50, 1 L/min) with subsequent cannulation of
the tail vein for drug/contrast agent administration. )e
animals were secured in a cradle (Rapid Biomedical GmbH,
Rimpar, Germany). )e heart rate, respiration rate, and
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rectal temperature were monitored (Model 1030 monitoring
and gating system, Small Animal Instruments Inc. Stony
Brook, NY, USA), with body temperature maintained at 37°C
by a heat fan. A 72mm quadrature volume coil was used for
transmission with signal reception by a four-channel phased-
array coil (Rapid Biomedical GmbH, Rimpar, Germany).
Scout images were taken to conﬁrm correct positioning
and to orientate 9× 2mm axial slices from the aortic valve
annulus to the apex, perpendicular to the interventricular
septum (short axis slices). )e slice plan was carefully
replicated between scans by ensuring the same slice plan
methodology, which was agreed by two operators at the time
of scanning to agree adequate orientation. Selection was then
made of the mid-ventricle short axis slice for further in-
terrogation with cine and the T1 mapping sequence. Long-
axis cines and a short-axis stack were acquired (to allow left
ventricular ejection fraction calculation), with cardiac-gated
gradient echo imaging (TR� 1×R-R interval; TE� 1.4ms;
ﬂip angle� 15°; FOV� 50× 50mm2; matrix� 128×128; slice
thickness� 1.5mm).
T1 mapping for calculation of regional left ventricular
myocardial T1 relaxation times was accomplished using
a gradient-echo, cardiac-gated Modiﬁed Look-Locker In-
version recovery sequence (MoLLI) [26] whereby 14–20
images were acquired at unique inversion times (dependent
on heart rate, ranging from approximately 0.20 to 3.00 s) with
the TRinversion> 3×T1 of myocardium (TRinversion> 4.50 s).
Imaging readout was with a cardiac fast gradient echo
(TR� 3.50ms; TE� 1.77ms; ﬂip angle� 10°, matrix 128×128;
ETL� 8; FOV� 50× 50mm2; in-plane resolution� 0.39×
0.39mm2; trigger delay� 1×R-R; slice thickness� 2mm; 8
signal averages) to compensate for respiratory motion.
2.2. Manganese-Enhanced MRI of Healthy Rat Myocardium.
EVP1001-1 (SeeMore™, Eagle Vision Pharmaceuticals Cor-
poration, Downingtown, PA, USA) was administered as an
intravenous bolus at the manufacturer’s recommended
dosage of 22 μmol/kg manganese over 3-4min. Mangafodipir
(Teslascan™, IC Targets AS, Oslo, Norway) was similarly
administered as a bolus of 22 or 44 μmol/kg manganese over
3-4min. Manganese chloride solution (MnCl2) was prepared
usingMnCl2·4H2O (Sigma-Aldrich Ltd, Gillingham, UK) and
sterile water (Sigma-Aldrich Ltd, Gillingham, UK), and
22 μmol/kg manganese was administered over 3-4min. All
manganese contrast media were delivered in volumes of
2.2mL/kg, diluted with 0.9% saline solution (Sigma-Aldrich
Ltd, Gillingham, UK), to maintain the rate of manganese
delivery constant between agents.
Diltiazem (Sigma-Aldrich Ltd, Gillingham, UK) diluted
with 0.9% saline solution was infused at 100μmol/kg/min in-
travenously, increased to approximately 120–200μmol/kg/min
until a satisfactory chronotropic response was achieved (re-
duction of >10% in heart rate) or the upper limit was reached.
Infusion was commenced approximately 10min prior to T1
mapping to ensure stable and adequate heart rate response.
Control administrations consisted of a similar volume
(8mL/kg) of 0.9% saline over 180min. Administration of all
agents was followed by a further saline ﬂush of 0.4mL to
ensure complete delivery to the circulation accounting for
dead space in the ﬁne-bore intravenous line. T1 mapping was
performed in all animals at baseline and then at approxi-
mately 5, 20, 40, and 60min after manganese contrast media
administration, while cine imaging was performed in a cohort
of animals at approximately 15, 30, and 50min after contrast.
)e time intervals were determined by technical consider-
ations relating to the length of time required for the T1
mapping sequences.
2.3. Myocardial Infarction Model. Rats were anaesthetised
with isoﬂurane (5% in 1.5 L/min oxygen for induction),
followed by intraperitoneal ketamine 100mg/kg (Zoetis Ltd,
London, UK) and medetomidine 1mg/kg (Orion Pharma,
Espoo, Finland) for maintenance anaesthesia. Buprenor-
phine 0.05mg/kg (Alstoe Ltd, York, UK) was administered
immediately before and 24 hours postoperatively for anal-
gesia. Tracheal intubation was achieved under direct vision,
and ventilation was maintained with a rodent ventilator
(Harvard Apparatus Model 683, MA, USA, tidal volume
2.5 cm3, respiratory rate 60/min).
Myocardial infarction was induced as we have previously
described [27]. Brieﬂy, the skin was incised at the level of the
left third and fourth ribs where the pectoral muscles were
divided and retracted. Left lateral thoracotomy was then
performed. With minimal handling, the pericardium was
ruptured and the heart gently exteriorised from the thorax,
and a nonabsorbable 5-0 ligature was placed around the left
anterior descending coronary artery just above the bi-
furcation of the ﬁrst diagonal and manoeuvred back into
position. Before wound closure, a drain was inserted to assist
with removal of air and ﬂuid from the thorax. Once re-
moved, the wound was then closed in three layers. Sham
animals underwent identical surgery with pericardial rup-
ture although the suture placed through the myocardium
was not tightened to cause infarction. Animals were re-
covered with intraperitoneal atipamezole 0.1mg/kg (Orion
Pharma, Espoo, Finland) and extubated once spontaneous
ventilation was established, housed at 30°C for 24 hours and
given sterile sodium chloride 0.9% 0.01mL/g ﬂuid therapy
subcutaneously. After 24 hours, normal housing conditions
were resumed.
2.4. Myocardial Infarction Imaging. )ree weeks post-
operatively, rats ﬁrst underwent DEMRI scanning, under
isoﬂurane anaesthesia as described above. Scout images were
taken to conﬁrm correct positioning and to orientate
9× 2mm axial slices from the aortic valve annulus to the
apex, perpendicular to the interventricular septum. Cine
images were then acquired in long- and short-axis views as
outlined above. Standard DEMRI inversion recovery was
performed using gadolinium complex (gadobendate dime-
glumine, Bracco S.p.A, Milan, Italy) with 0.5mmol/kg ad-
ministered intravenously via slow injection into the tail vein
over 1-2min. Standard inversion recovery prepared imaging
with myocardial nulling was performed 10min following
injection (inversion recovery gradient echo, TI� 2.3×R-R
(typical R-R 150–200ms), TR≈ 500ms; TE� 1.6ms; ﬂip
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angle� 90°; FOV� 50× 50mm2; matrix� 128×128). Due to
information gained from the healthy animal data with the
manganese contrast agent experiments (Section 3) as well as
technical considerations (i.e., pulse sequence duration),
DEMRI T1 mapping was performed at 20min following
contrast injection upon completion of inversion recovery, at
the maximal infarct slice as deﬁned by the cine images
(MoLLI: TR> 4.5 sec; TE� 1.7ms; ﬂip angle� 10°;
matrix� 128×128; ETL� 8; FOV� 50× 50; 20 time points;
trigger delay� 1×R-R; slice thickness� 2mm; 8 signal av-
erages). Animals were allowed to recover following the scan.
MEMRI was performed 48 h after the DEMRI protocol.
Scout images were taken followed by a single short-axis cine
at the maximal infarct slice, using the method outlined
above. MEMRI T1 mapping was then achieved using one of
the two manganese-based MRI contrast media being de-
veloped for clinical use; EVP1001-1 (n � 8) and man-
gafodipir (n � 9) at doses of 22 and 44 μmol/kg, respectively,
administered via slow intravenous injection into the tail vein
over 1-2min. T1 mapping was performed at the maximal
infarct slice (EVP1001-1, 20min after injection; man-
gafodipir 40min after injection) deﬁned by the DEMRI scan
acquired in the ﬁrst imaging session. )e doses selected of
EVP1001-1 and mangafodipir and the timings of the T1
mapping sequences after manganese contrast agent ad-
ministration were informed by the healthy animal data to
ensure similar degrees of T1 enhancement and therefore
sensitivity to detect myocardial viability. Finally, a cine
acquisition in the short axis at the maximal infarct slice was
repeated following contrast injection. Animals were allowed
to recover following the scan.
At 12 weeks after surgery, DEMRI and MEMRI (48 h
apart) were repeated using the identical protocols described
above. Animals received the same manganese contrast agent
at both time points. MRI parameters were unchanged with
the exception of an increased FOV (55× 55mm) on account
of growth of the animals. After the second MEMRI scan,
animals were culled by exsanguination by femoral puncture
under anaesthesia for tissue harvest. Figure 1 displays a ﬂow
chart summarising the imaging of the myocardial infarction
cohort.
2.5. Pathology. Hearts were ﬁxed by immersion in 4%
paraformaldehyde for 24 hours before being transferred to
70% ethanol and processed to paraﬃn wax for sectioning
thereafter. Serial 5 µm sections were taken at intervals in
the short axis from apex to base, corresponding to MRI
short axis T1 mapping data. Staining was performed with
Masson’s trichrome (MTC) to delineate areas of collagenous
ﬁbrosis, staining infarct blue, and noninfarct purple, before
mounting for computer-aided analysis. Slides were scanned
at 20x magniﬁcation on a Zeiss Axio Scan Z1 (Carl Zeiss AG,
Oberkochen, Germany) with infarct size calculated as
a percentage of total left ventricular area at the comparable
maximal infarct slice deﬁned by MRI. Automated tissue
detection was conducted using Tissue Studio v2.4 (Deﬁniens
AG, Munich, Germany) as follows: a training set of 4 images
was automatically segmented, and segments within three
50× 50 µm regions comprising remote myocardium, infarct,
and cross-over regions from each training image (12 regions
in total) were manually classiﬁed as “Normal myocardium,”
“Collagen,” and “nontissue.” )ese manual classiﬁcation
samples were used to train the software’s automated classi-
ﬁcation algorithm which was then applied to all images in the
dataset. Automated detection produced pixel counts and
areas for the ROIs within the left ventricle, from which
percentage infarct area at maximal infarct slice was calculated.
2.6. Image Analysis. Quantitative analysis of manganese
accumulation was achieved by calculation of regional T1
relaxation times before and after administration of man-
ganese contrast media. )e 14–20 images at unique in-
version times were exported oﬄine and combined to
generate T1 maps using commercially available software
(CVI4.2®, Circle Cardiovascular Imaging, Calgary, Canada)
using three-parameter nonlinear curve ﬁtting as previously
described [15].
During the lengthy in vivo experiments, it was noted that
there was an approximate ±10% variation in the measure-
ment of T1 values in healthy myocardium and skeletal
muscle before the administration of manganese contrast
agents. In an attempt to compensate for these ﬂuctuations in
T1 measurements, myocardial T1 values were normalized to
the T1 of skeletal muscle, where it was noted that the T1
values did not vary over the time course of the contrast agent
infusion (as detailed in Section S1 of Supplementary Ma-
terials). Final normalized T1 maps were then generated in
Matlab (MathWorks, Inc., USA) with normalized myocar-
dial T1 values obtained from regions of interest (ROIs)
drawn on the left ventricle. Change in T1 between the
baseline myocardial T1 and the myocardial T1 at each time
point was then calculated (ΔT1). Infarct was deﬁned as 2x
standard deviations of infarcted and remote myocardial T1
with an averaged intermediate value representing border-
zone myocardium.
2.7. Statistical Analysis. Data are presented as mean±
standard deviation unless otherwise stated. Comparison of
the time course curves between the saline (control) and
diltiazem-infused groups for each of the 22 μmol/kg MnCl2,
22 μmol/kg EVP1001-1, and 44 μmol/kg mangafodipir was
performed using a two-way analysis of variance (ANOVA)
with post hoc multiple comparison Bonferroni tests for
individual time points (compared to baseline). For infarct
quantiﬁcation, DEMRI inversion recovery, DEMRI T1
mapping, MEMRI T1 mapping, and MTC assessments were
compared using Wilcoxon signed-rank test (2-tailed), with
post hoc multiple comparison Bonferroni testing. Bland–
Altman plots were used to assess agreement between DEMRI
inversion recovery, DEMRI T1 mapping, MEMRI T1 map-
ping and MTC, and Pearson correlation tested for re-
lationship between changes in remote T1 between early and
late time points (ΔT1, dependent variable) and ejection
fraction (independent variable). Statistical analysis was
performed using GraphPad PRISM (v.7.0, GraphPad
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Software, Inc., La Jolla, CA, USA). Statistical signicance was
taken as two-sided P< 0.05.
3. Results
3.1. Comparative and Calcium-Channel Dependency of
MEMRI Contrast Media. irty-one animals underwent
experiments with the manganese contrast agent with a con-
current infusion of either 0.9% saline or diltiazem at a median
age of 84± 19 days, with a median weight of 356± 45 g. Four
animals (two control and two with diltiazem) were excluded
as venous access was compromised resulting in unpredictable
contrast agent administration. MnCl2, EVP1001-1, and
mangafodipir altered T1 relaxivity values evident with T1
mapping (Figure 2(a)). Mean shortening of myocardial T1
values was greater with EVP1001-1 as compared with similar
concentrations of mangafodipir but commensurate to those
observed with MnCl2 (Figure 2(b)). Peak changes in T1 values
were obtained by 20min with EVP1001-1 and MnCl2, with
persistent T1 shortening at 60min. e magnitude of T1
shortening was dose-dependent for mangafodipir with little
change between 40 and 60min time points (Figure 2(b)).
Overall T1 shortening with MnCl2, EVP1001-1, and man-
gafodipir (all 22 μmol/kg) at 20min were 29.4± 5.1%, 28.0±
4.4%, and 8.5± 4.2%, respectively. To improve the degree of
T1 shortening with mangafodipir, the dosage of manganese
administered was increased to 44 μmol/kg resulting in a T1
shortening of 12.8± 3.4% at 20min which increased to 15.0±
2.9% at 40min. MnCl2 and EVP1001-1 values at 40min after
administration were unchanged.
Pre-treatment with a calcium-channel antagonist (dil-
tiazem) inhibited MEMRI-induced T1 shortening (Table 1).
is inhibition was similar between all agents with MnCl2
experiencing a maximal mean reduction of 30% in T1
shortening between the 5 and 60min time points, while
EVP1001-1 and mangafodipir experienced reductions of
up to 43% and 32%, respectively. ere were signicant
dierences between the degree of myocardial T1 shortening due
to eachmanganese contrast agent in the presence of diltiazem as
measured by two-way ANOVA (MnCl2 P< 0.0004, EVP1001-1
P< 0.0001 and mangafodipir P  0.044).
3.2. Left Ventricular Function. All contrast agents were well
tolerated across all animal groups. Following administration
of gadolinium and EVP1001-1, a transient increase in the
respiratory rate was observed, which was self-limiting and
resolved within 1 minute. is was seen in healthy animals,
shams, and infarcted animals. e present study was not
designed to assess safety and tolerability, and no further
adverse eects were observed.
Healthy myocardial left ventricular ejection fraction was
measured before and after manganese contrast agent ad-
ministration to assess for discernible myocardial depression.
e mean LVEF (±standard deviation) and the mean dif-
ference in LVEF at each time point from the cohorts of
healthy rats administered with each of the manganese
contrast agents with concurrent diltiazem (or 0.9% saline
control) infusion are shown in Table 2.
No dierence was noted between the mean dierence in
LVEF between baseline and the time points between
mangafodipir 22 μmol/kg and mangafodipir 44 μmol/kg
(P  0.78) by two-way ANOVA indicating that the higher
mangafodipir dosage was well tolerated. ere were sig-
nicant dierences detected between the mean dierence in
LVEF with each of the contrast agents in the presence of
diltiazem: MnCl2 22 μmol/kg (P< 0.001 and signicant
(P< 0.05) at the 15min and 50min time points on multiple
comparison); EVP1001-1 (P  0.02) and mangafodipir
44 μmol/kg (P  0.04). is may potentially indicate that in
the presence of depressed LVEF the manganese contrast
agents at the dosages used may further compromise myo-
cardial contractility; however, further study would be re-
quired beyond this preclinical study with low numbers of
n = 5
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Figure 1: Myocardial infarction experimental protocol. Flow chart detailing timing of surgery and imaging with dierent contrast agents.
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animals. ere was no change in left ventricular ejection
fraction following manganese administration with any of the
agents in the saline control animals. ese data support the
assertion that there is minimal change in left ventricular
myocardial function in healthy animals with the dosages
used in this study. In the infarct group, left ventricular
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Figure 2: T1 shortening of manganese contrast media over time. (a) Normalized T1 maps acquired subsequent to infusion of MnCl2,
EVP1001-1, and mangafodipir at 20 minute intervals up to 60 minutes, with associated gradient echo cine images in end-diastole and end-
systole. MnCl2 (22 μmol/kg), EVP1001-1 (22 μmol/kg) or mangafodipir (44 μmol/kg) was administered intravenously to isourane-
anaesthetised healthy rats over 3-4 minutes. Rats were simultaneously administered an infusion of 8mL/kg 0.9% saline over 3-4 minutes.
Note the superior degree of T1 shortening with MnCl2, and EVP1001-1 at half the molar dosage of manganese as compared with
mangafodipir (T1 reduction of 421.3ms and 357.9ms from baseline with MnCl2 and EVP1001-1 compared with 222.7ms with man-
gafodipir). (b) Reduction in mean left ventricular T1 values over 60 minutes with EVP1001-1 and mangafodipir. MnCl2 (22 μmol/kg; blue),
EVP1001-1 (22 μmol/kg; red), mangafodipir (22 (green) or 44 (purple) μmol/kg) was administered to rats (n  4 per group) over 3-4min.
Error bars represent standard deviations from time points wheremeasurements were recorded (n  4 at each time point). Two-way ANOVA
conrmed a dependence of mean myocardial T1 shortening between each of the contrast agents (P< 0.0001).
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function was assessed at the maximal infarct slice by frac-
tional area change (single slice only due to concern over
prolonged anaesthetic risk) before and after manganese-
based contrast media administration to assess for discern-
ible myocardial depression. )ere was no change in frac-
tional area change at this slice following administration of
either EVP1001-1 or mangafodipir at early (0.1± 1.5%, P �
0.82 and 0.1± 2.2%, P � 0.88) or late (0.2± 1.2%, P � 0.74
and 0.3± 1.8%, P � 0.70) imaging time points, respectively.
3.3. Eﬀect of T1 Relaxivity of Contrast Media. On comparison
of the eﬀect of diﬀerent contrast agents on T1 relaxivity, the
diﬀerence in mean T1 between infarcted and remote myo-
cardiumwas highly signiﬁcant across all contrast agents as well
as native T1 mapping. Remote myocardial mean T1 was similar
between both mangafodipir and EVP1001-1 (Figure 3).
3.4. Viability Assessment after Myocardial Infarction.
Eighteen animals underwent successful surgery (14 per-
manent coronary artery ligation surgery, 4 sham surgery)
at a median age of 58 ± 7 days, with a median weight of
262 ± 52 g. One animal in the surgical cohort died un-
expectedly 11 days after surgery, resulting in 17 animals
completing the experimental imaging protocol. Another
animal died unexpectedly 31 days after surgery, with large
myocardial infarction, a likely substrate for ventricular
arrhythmia as previously observed [28], and 2 animals
failed to recover from MRI at the late time point.
)ree weeks following surgery, all animals in the infarct
cohort had left ventricular impairment with anterior wall
akinesis and wall thinning associated with a reduced left
ventricular ejection fraction (42.2± 8.1 versus 68.9± 9.4% in
sham animals, P< 0.001). Myocardial infarction was also
associated with higher left ventricular end diastolic volume
(1.0± 0.2 versus 0.7± 0.1mL, P � 0.02) and mass (0.7± 0.1
versus 0.6± 0.04 g, P � 0.03). )ere were no diﬀerences in
left ventricular function nor volume between animals ad-
ministered mangafodipir or EVP1001-1 (left ventricular
ejection fraction, 41.49± 9.86 and 43.10± 6.44%, respec-
tively, P � 0.76; left ventricular end diastolic volume, 1.02±
0.21 versus 0.83± 0.07mL, respectively, P � 0.18).
After surgery, infarct size at the maximal infarct slice was
smaller when assessed by MEMRI than DEMRI at 3 weeks
Table 1: Eﬀect of diltiazem on manganese-induced T1 shortening.
Time point (minutes) Baseline T1 (ms)
Mean T1 shortening (ms)
5 20 40 60
MnCl2 + saline 1286± 42 366± 72 382± 72 389± 67 351± 35
MnCl2 + diltiazem (n � 3) 1180± 93 290± 52 288± 71 276± 56 274± 63
EVP1001-1 + saline 1265± 94 354± 91 397± 73 352± 54 383± 87
EVP1001-1 + diltiazem 1375± 38 209± 27∗ 225± 57∗ 211± 49 226± 40∗
Mangafodipir + saline 1366± 94 142± 52 178± 59 206± 53 220± 61
Mangafodipir + diltiazem 1219± 69 96± 34 128± 42 158± 66 177± 24
Healthy rats (group sizes n � 4 unless otherwise stated) administered MnCl2 (22 μmol/kg), EVP1001-1 (22 μmol/kg), or mangafodipir (44 μmol/kg) over 3-
4min with simultaneous administration of 0.9% saline or diltiazem (100–200 µmol/kg/min) infusion. Note the approximate 30% reduction in mean
myocardial T1 values at each time point, but that there is greater discrimination between the diltiazem and saline infused rats due to the superior T1 shortening
with EVP1001-1. Post hoc Bonferroni multiple comparisons (manganese agent + saline; manganese agent + diltiazem). Signiﬁcance P< 0.05 at each time
point as compared with saline control is indicated by asterisk.
Table 2: Mean LVEF and mean diﬀerence in LVEF versus baseline for the cohort of healthy rats administered MnCl2, EVP1001-1, and
mangafodipir.
Time point (minutes)
Mean LVEF (%) and mean diﬀerence in LVEF (%)
Baseline 15 30 50
MnCl2 + saline 67.5± 5.6 73.4± 6.3 72.4± 5.6 71.1± 2.0
Mean diﬀerence (vs. baseline) — 5.8± 1.3∗ 4.9± 2.6 3.6± 5.1∗
MnCl2 + diltiazem 65.0± 8.0 58.2± 3.9 58.3± 6.8 60.1± 12.5
Mean diﬀerence (vs. baseline) — −3.2± 0.6∗ −3.1± 2.6∗ −4.8± 5.1∗
EVP1001-1 + saline 65.3± 0.7 71.0± 5.5 67.1± 2.5 67.1± 3.8
Mean diﬀerence (vs. baseline) — 4.0± 6.8 −0.3± 2.6 0.7± 5.5
EVP1001-1 + diltiazem 69.6± 6.4 68.3± 8.4 63.4± 7.3 65.6± 7.8
Mean diﬀerence (vs. baseline) — −0.5± 3.7 −4.1± 4.0 −4.1± 3.7
Mangafodipir 22 μmol/kg 63.2± 6.3 66.9 (n � 2) 65.8± 8.2 67.1± 7.4
Mean diﬀerence (vs. baseline) — 6.9 (n � 2) 4.7± 7.1 2.5± 4.5
Mangafodipir 44 μmol/kg + Saline 73.5± 3.1 76.8 (n � 2) 76.1± 4.9 77.0± 4.1
Mean diﬀerence (vs. baseline) — 3.9 (n � 2) 4.5± 1.1 4.6± 3.6
Mangafodipir 44 μmol/kg + diltiazem 64.1± 4.8 64.0± 8.1 62.5± 7.3 62.0± 9.5
Mean diﬀerence (vs. baseline) — 0.81± 6.53 −0.2± 6.9 −1.0± 4.7
Group sizes n � 3 for EVP1001-1 andmangafodipir 22 μmol/kg and n � 4 forMnCl2 andmangafodipir 44 μmol/kg. Calculation of mean only from those time
points with n � 2 measurements available. Post hoc Bonferroni multiple comparisons signiﬁcance P< 0.05 at each time point as compared to saline control
indicated by asterisk.
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(17.4± 8% versus 28.5± 13%, P< 0.05), although the dif-
ferences were less marked by 12 weeks (20.4± 9% versus
28.6± 8%, P  0.067, Figure 4).
At 12 weeks, DEMRI inversion recovery, DEMRI T1
mapping, and MEMRI T1 mapping of infarct size all cor-
related independently with histologically quantied infarct
size by MTC (all P< 0.05). However, unlike manganese,
gadolinium-based assessments tended to overestimate in-
farct size by around 10% (DEMRI inversion recovery, bias
11.36%, 95% condence intervals −9.11 to 31.82, P  0.002;
DEMRI T1 mapping, bias 8.25 %, 95% condence intervals−10.7 to 27.2, P  0.008; MEMRI T1 mapping, bias 1.14 %,
95% condence intervals −14.8 to 17.1, P  0.735; with
post hoc Bonferroni multiple comparisons for P< 0.05,
Figures 5(a) and 5(b)).
ere was an inverse correlation between ejection
fraction and remote myocardial ∆T1 (r  −0.61, P  0.022;
Figure 6) with greater reduction in remote myocardial T1 at 3
months with increasing severity of left ventricular impair-
ment. Myocardium remote from the site of infarction (mean
T1 of noninfarcted myocardium) appeared to have lower
meanMEMRI T1 mapping values at late (12 week) compared
with early (3 week) time points in animals with the largest
infarcts by ejection fraction, but this was not statistically
signicant (mean ∆T1 −8.39± 0.66%, P  0.4, n  3; sham
animals with preserved left ventricular ejection fraction
mean ∆T1 7.19± 5.93%, P  0.7, n  3).
4. Discussion
e present study applies myocardial T1 mapping to
manganese-enhanced MRI, in healthy myocardium in
addition to remote myocardium after infarction. is novel
combination of imaging techniques has been employed to
directly compare two distinct manganese contrast agents
with conventional DEMRI in the assessment of viability by
infarct size, as well as examine altered calcium handling in
remodelling myocardium over time, building on previous
pilot data in myocardial infarction. is work was designed
as a precursor to clinical translation of intramyocardial
contrast imaging, for development of this promising eld
within cardiac MRI which has potential to improve accuracy
of myocardial viability assessment, improve understanding
of pathophysiology, and monitor response to therapy in
dierent forms of cardiomyopathy.
We have demonstrated that MEMRI causes an ionic,
concentration, and calcium channel-dependent shortening of
myocardial T1 values. We have further shown that MEMRI T1
mapping provides a better estimate of infarct size than
DEMRI using both inversion recovery and T1 mapping and
correlates with left ventricular remodelling within the remote
myocardium following myocardial infarction. We conclude
that MEMRI holds major potential for the assessment of
myocardial viability, dysfunction, and regeneration with
a wide range of clinical applicability.
4.1. Chelation, Concentration, and Calcium-Channel
Dependence. Biotransformation of MnDPDP occurs by
dephosphorylation and simultaneous transmetallation with
zinc facilitating MRI-detectable intracellular manganese
uptake, as demonstrated in vitrowhere transmetallation with
zinc occurs rapidly, almost to completion, within 1 minute
of incubation in human serum [29]. ese ndings have
been reinforced in subsequent animal [30, 31] and human
studies [32, 33]. In the present study, chelated (man-
gafodipir) and nonchelated (MnCl2 and EVP1001-1) man-
ganese contrast media were compared in healthy
myocardium. Intracellular T1 shortening properties of
manganese were clearly demonstrated with a reduction in
myocardial T1 values of 29.4± 5.1%, 28.0± 4.4% and 12.8±
3.4%, compared with baseline values, with 22 μmol/kg
MnCl2 and EVP1001-1 at 20min, and 44 μmol/kg man-
gafodipir at 40min, respectively. e paramagnetic per-
formance of manganese when administered as EVP1001-1
was highly comparable to that of MnCl2, with rapid increase
in T1 relaxivity over time achieving close to maximal
relaxivity by 5min (Figure 2(a)). is correlation is expected
given intravenous administration of nonchelatedmanganese
ions in both cases. is eect on T1 shortening was sustained
at 60min and an optimal imaging time point of 20min was
adopted to allow for variation in administration dynamics
and utilised in the infarcted myocardium MEMRI experi-
ments. A less marked increase in relaxivity was observed
with mangafodipir. is is likely to be due to the need for
manganese to become unchelated from the DPDP ligand as
above. To achieve reduction in T1 comparable with the
nonchelated preparations, the dose of mangafodipir was
doubled to 44 μmol/kg to obtain similar reductions in
myocardial T1 (Figure 2(b)). T1 relaxivity continued to in-
crease over the measured time period although appeared
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Figure 3: Comparison of the eects of contrast agents on T1
relaxivity. Mean T1 is signicantly dierent between remote and
infarcted areas of myocardium for all agents and native T1 mapping
(all P< 0.0001). Remote myocardial T1 between manganese con-
trast agents was comparable (P  0.064).
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Figure 4: Comparison of DEMRI and MEMRI infarct quantication by T1 mapping. Mean infarct size as a percentage of left ventricular
myocardium at maximal infarct short-axis slice in rats with DEMRI and MEMRI T1 mapping at two time points; early post-MI (3 weeks,
n  13, left panel) and late post-MI (12 weeks, n  12, right panel). Infarct size as assessed by MEMRI T1 mapping is signicantly lower than
DEMRI T1 mapping at 3 weeks (P< 0.05), a result which is attenuated at 12 weeks (P  0.067). Error bars represent standard deviation.
Example T1 maps with delayed enhancement and gradient echo cine images are shown for one animal.
18.24%
17.61%
15.77%
10.41%
16.73%
12.78%
DEMRI MEMRI MTC
Low T1
High T1
Low T1
High T1
(a)
10 20 30 40 50
–20
0
20
40
Average
D
iff
er
en
ce
(i)
Bias 
11.36
10 20 30 40 50
–20
0
20
40
Average
D
iff
er
en
ce
D
iff
er
en
ce
(ii)
Bias 
8.25
10 20 30 40 50
–20
0
20
40
Bias 
1.14
(iii)
Average
(b)
FIGURE 5: DEMRI versus MEMRI vs MTC. (a) Comparison of magnetic resonance imaging and histological quantication of infarct size.
Infarct size as a percentage of left ventricular myocardium at maximal infarct short-axis slice by DEMRI and MEMRI T1 mapping and
histologically with MTC. Note the inverted T1 colour map conguration between DEMRI T1 mapping and MEMRI T1 mapping, calibrated
to dene infarct (pink) and remote (green) myocardium with intermediate values (yellow). (b) Bland–Altman plots showing dierences
between DEMRI inversion recovery (A), DEMRI T1 mapping (B), and MEMRI T1 mapping (C) for each rat heart. e average dierence
(bias) between the measurements is shown (dashed lines) ±2× SD (dotted lines) for all three modalities.
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to begin to plateau from 40min after administration.
An imaging time point of 40min was selected as a com-
promise between practicability and allowing adequate time
for unchelation of manganese to achieve su«cient in-
tracellular uptake and therefore provide adequate T1
shortening. Inhibition of intracellular manganese uptake
was evident from a consistently reduced T1 shortening
observed with MnCl2, EVP1001-1, and mangafodipir
when coadministered with diltiazem (Table 1). A benzo-
thiazepine, diltiazem binds to L-type calcium channels at
cardiac myocytes and decreases myocardial contractility [8].
Coadministration with manganese-based contrast agents
serves to assess manganese uptake in myocardium during
calcium-channel inhibition. Myocardium in animals pre-
treated with diltiazem showed reduction in mean shortening
of myocardial T1 values with both clinical-grade agents, but
the magnitude of inhibition was greater with EVP1001-1
compared with similar concentrations of mangafodipir. Due
to the superior T1 shortening with EVP1001-1 at lower
doses, there are potentially greater dierences between the
diltiazem and saline infused animals. ese data reinforce
the understanding that intracellular manganese uptake is
dependent on both L-type voltage-gated calcium channel as
well as sodium/calcium exchanger activity, as previously
demonstrated [34].
4.2. MEMRI in Myocardial Infarction. In myocardial in-
farction, both DEMRI inversion recovery and T1 mapping
consistently overestimated infarct area 3 weeks after sur-
gery in comparison with MEMRI T1 mapping. Both
DEMRI and MEMRI modalities correlated with histo-
pathological infarct quantication by MTC. However,
infarct quantication was similar for histopathology and
MEMRI T1 mapping, whereas DEMRI consistently over-
estimated infarct size. Contrast imaging of acute myo-
cardial infarction with DEMRI inversion recovery is well
established to overestimate infarct size due to
pathologically expanded extracellular space and myocar-
dial oedema. is nding has been observed with pre-
clinical data from swine ischaemia-reperfusion injury
indicating discrepancy between DEMRI inversion recovery
(both in vivo and ex vivo) and histological infarct size at 6 h,
resolving at 7 days [35]. In clinical studies, imaging too
early after infarction results in enhancement of salvaged as
well as infarcted myocardium [5] and some degree of
myocardial oedema remains and is stable for 7 days fol-
lowing myocardial infarction, reducing at 14 days and
near-normalising at 6 months [36]. MEMRI mechanisti-
cally circumvents the uncertainty of myocardial oedema as
it acts as a specic intracellular agent tracking car-
diomyocytes with functional calcium handling. Further-
more, permanent arterial occlusion models, as used in the
present surgical protocol, result in substantially less
myocardial interstitial oedema than ischaemia-reperfusion
models, even at 24 h [37]. In the present study, gross
myocardial oedema is therefore unlikely to persist at 3
weeks, implicating other factors to account for over-
estimation of infarct size by DEMRI techniques. We
hypothesise that dual enhancement with both gadolinium
and manganese may occur in areas of injured myocardium
where there is residual calcium transport functionality.
Early clinical work has explored MEMRI T1 mapping as
a technique to dene viability in this way using man-
gafodipir, demonstrating manganese enhancement in
myocardium remote to the infarcted region, 3-4 weeks after
infarction [38]. Whilst MnCl2 carried signicant risk of
adverse events in cardiac patients which prohibits further
clinical development, mangafodipir and EVP1001-1, both
having established clinical safety and tolerability, are now
primed for clinical applications in cardiac imaging. e
clinical signicance of viable myocardium dened in this
way is as yet unknown and underscores the need for robust
clinical trials in this eld.
4.3. Detection of Altered Calcium Handling with MEMRI.
T1 mapping of remote myocardium was compared over time
following myocardial infarction allowing time for left ven-
tricular remodelling. Changes in T1 values between early and
late time points were compared for each animal. Despite
variability between animals, an inverse correlation was
observed between ejection fraction and change in T1 value
for all animals, including shams.e signicance and precise
mechanisms underlying this preliminary nding are un-
conrmed as there are contradictory data on activity of
voltage-gated L-type calcium channels in heart failure.
L-type calcium channels in remodelling remote myocar-
dium may have a greater propensity to remain open for
longer, on account of prolongation of the plateau phase of
the cardiac action potential, as compared with uninjured
myocardium resulting in greater relative manganese uptake
[39]. A study analysing cardiomyocytes from failing hu-
man myocardium observed enhancement of single L-type
calcium-channel activity compared with nonfailing con-
trol myocardium, demonstrating both increased avail-
ability and open probability [40]. e data from the
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Figure 6: ∆T1 in remote myocardium over time versus ejection
fraction. Correlation of change in remote myocardial T1 relaxivity
between early and late time points with ejection fraction at 12 weeks
after surgery. ere is a signicant correlation between ejection
fraction and T1 reduction between early (3 week) and late (12 week)
time points (r  0.61, P  0.022). Standard error of the mean
shown as dashed black line.
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present study indicate potential for MEMRI to characterise
disordered calcium handling in failing myocardium, but
this requires further exploration in clinical translational
studies.
4.4. Challenges of the Preclinical Model. )e present study
has been designed as a proof-of-concept study of MEMRI in
ischaemic cardiomyopathy to inform clinical translation of
this imaging modality in ischaemic heart disease as well as
other forms of cardiomyopathy. )e aim was to assess the
application of manganese in noninfarcted myocardium
undergoing remodelling following infarction rather than
speciﬁc dynamics of the infarct region acutely after in-
farction. )erefore, a permanent coronary artery ligation
model was used over an ischaemia-reperfusion model. )ere
are several aspects that are speciﬁc to preclinical MR imaging
of rodents which do not apply to clinical imaging which are
relevant. Despite the excellent spatial resolution of the T1
mapping sequence used in this study, the small myocardial
volume in conjunction with heart rates in excess of 350 beats
per minute, obligate free-breathing acquisition with re-
spiratory rates in excess of 40 breaths per minute (with
a high degree of variability in both these parameters) provide
signiﬁcant challenges resulting in prolonged T1 mapping
sequences (11–13 minutes) and the margin for error is
consequently much narrower than in a clinical equivalent.
)is constraint resulted in the practical requirement to select
one slice representative of the myocardial infarction, rather
than acquire a full T1 map short-axis stack. )e potential for
sampling error between scans was minimized by careful
adjudication by two experienced operators at the time of
scanning to agree adequate orientation and replicate slice
planning methodology, as described above. Whilst unable to
guarantee maximal infarct slice, this ensures equivalent slice
comparison between scans.
)e use of T1 mapping removes the issue of timing in
correct nulling, which is made problematic due to the
animal-speciﬁc issues above. In the imaging of an infarct, it
is possible to select an inversion time following manganese
administration whereby the infarct is nulled and the myo-
cardium enhances, in an opposite fashion to DEMRI with
gadolinium. Inversion recovery imaging with these nulling
techniques is easily degraded by artefact of irregular heart
rate or breathing and accurate conclusions are highly de-
pendent on the quality of the nulling. Moreover, where more
diﬀuse myocardial processes are concerned, such as remote
remodelling in ischaemic cardiomyopathy, T1 mapping
oﬀers the ability to quantify the graduation of T1 across all
regions of myocardium. Finally, in clinical MR imaging,
a motion correction algorithm is applied to the T1 mapping
sequence. )is algorithm is not available to us in the pre-
clinical setting. )ese technical factors, unique to the pre-
clinical nature of this study, necessitated the use of
normalization of T1 values and underscore the need for
clinical translation.
4.5. Clinical Perspectives. What future diagnostic and
therapeutic possibilities does manganese-enhanced cardiac
MRI oﬀer the clinician? )e prospect of intracellular
myocardial tissue characterisation is novel and has far
reaching potential. )e present study demonstrates unique
description of myocardial infarction and viability through
calcium handling which has exciting applications in de-
velopment of novel therapies in myocardial infarction,
recently explored in preclinical ischaemia-reperfusion
assessing myocardial regeneration with stem cell therapy
[13] and clinical work establishing safety and tolerability of
chelated manganese contrast agents in ischaemic heart
disease [23]. Beyond myocardial infarction, we have
demonstrated potential to detect altered calcium handling
noninvasively and scope for earlier detection and quanti-
ﬁcation of cardiomyopathy. )e present preclinical study
highlights the need for clinical translation of these agents,
where image acquisition is vastly superior, in a patient
population which accurately represents the substrate for
disease underlying the pathology.
5. Conclusion
)e present study demonstrates the utility of MEMRI with
two distinct agents, chelated and nonchelated manganese,
as a noninvasive imaging modality which can accurately
quantify viable myocardium. Furthermore, these data in-
dicate an ability to detect and quantify altered calcium
handling in the remodelling remote myocardium. )is
novel technique has potential to actively quantify viable
myocardium, rather than inferring viability using infarct
extent as a surrogate. Furthermore, calcium-handling
dysfunction observed in a wide range of cardiomyopa-
thies and heart failure syndromes eludes current
noninvasive investigation, an application where MEMRI
holds great promise. Clinical translation of the work
presented here is an essential next step.
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